Insulet (NASDAQ: PODD) Downgraded to Hold by Truist Financial Amid Sales Forecast Revision

• Truist Financial downgraded Insulet (NASDAQ: PODD) to Hold from Buy, citing a revised sales forecast for its Omnipod insulin management system.
• Despite a significant stock drop to $133.26, the new price target of $153.00 still suggests a 14.81% potential upside for the medical device company.
• Insulet demonstrated strong Q2 financial performance with total revenue of $801.7 million, a 23.5% increase, and adjusted earnings per share (EPS) of $1.66, up 41.5%.

On August 5, 2026, an analyst from Truist Financial changed their rating on Insulet (NASDAQ: PODD) to Hold from Buy. Insulet is a medical device company that develops and sells the Omnipod insulin management system for people with diabetes management. The firm also set a new price target of $153.00 for Insulet.

The downgrade follows Insulet's decision to lower its annual sales growth forecast, as highlighted by Reuters. The company now expects a softer second half of the year, especially for U.S. sales of its Omnipod pumps. This news caused the stock to fall significantly, trading at $133.26.

Despite the downgrade, the new price target implies a potential upside of 14.81% from its current price. The stock's decline to a new 52-week low reflects investor concern over the revised full-year U.S. Omnipod revenue growth, which is now projected to be between 17% and 19%.

This cautious outlook contrasts with strong recent financial performance. In its second quarter, Insulet reported total revenue of $801.7 million, a 23.5% increase from the previous year. Adjusted earnings per share (EPS), which shows profit per share, also grew by 41.5% to $1.66, beating analyst estimates, as highlighted by Zacks.

Profitability metrics also show improvement. The company's adjusted gross margin, the profit made on products sold, increased to 72.9%. While U.S. Omnipod revenue grew by 20%, international revenue saw a more significant rise of over 35%, showing strong growth outside of the United States.